New drug combo shows promise in Hard-to-Treat cancers
NCT ID NCT02379416
First seen Mar 06, 2026 · Last updated May 14, 2026 · Updated 7 times
Summary
This early-phase trial tested whether adding nilotinib (a pill) to paclitaxel (a standard chemo drug) could safely treat advanced solid tumors that had stopped responding to other therapies. 47 adults and children aged 12 and older took part. The goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling difficult cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.